Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by VALNEVA
< Previous
1
2
3
4
Next >
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
December 20, 2023
From
VALNEVA
Via
GlobeNewswire
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
December 04, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
December 04, 2023
From
VALNEVA
Via
GlobeNewswire
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
November 27, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
November 15, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
November 13, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
November 10, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
November 09, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
November 07, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
October 25, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
October 11, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
September 25, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
September 21, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
September 07, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
August 31, 2023
From
VALNEVA
Via
GlobeNewswire
Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review
August 29, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
August 28, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Extension of Existing Loan Agreement
August 17, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
August 14, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors
June 22, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
June 21, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
June 13, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
May 31, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces the Availability of Documentation for its Shareholder Meeting
May 31, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Files for Chikungunya Vaccine Authorization with Health Canada
May 30, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 04, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F
March 31, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
March 30, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
March 23, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
March 02, 2023
From
VALNEVA
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
